Efficacy of TG101348, a Selective JAK2 Inhibitor, in Treatment of a Murine Model of JAK2V617F-Induced Polycythemia Vera Academic Article uri icon


MeSH Major

  • Amino Acid Substitution
  • Disease Models, Animal
  • Janus Kinase 2
  • Polycythemia Vera
  • Protein Kinase Inhibitors
  • Pyrrolidines
  • Sulfonamides


  • We report that TG101348, a selective small-molecule inhibitor of JAK2 with an in vitro IC50 of approximately 3 nM, shows therapeutic efficacy in a murine model of myeloproliferative disease induced by the JAK2V617F mutation. In treated animals, there was a statistically significant reduction in hematocrit and leukocyte count, a dose-dependent reduction/elimination of extramedullary hematopoiesis, and, at least in some instances, evidence for attenuation of myelofibrosis. There were no apparent toxicities and no effect on T cell number. In vivo responses were correlated with surrogate endpoints, including reduction/elimination of JAK2V617F disease burden assessed by quantitative genomic PCR, suppression of endogenous erythroid colony formation, and in vivo inhibition of JAK-STAT signal transduction as assessed by flow cytometric measurement of phosphorylated Stat5.

publication date

  • April 8, 2008



  • Academic Article



  • eng

Digital Object Identifier (DOI)

  • 10.1016/j.ccr.2008.02.009

PubMed ID

  • 18394554

Additional Document Info

start page

  • 311

end page

  • 20


  • 13


  • 4